Efficacy of CeraVe® Moisturizing Cream on Skin Pruritus in Elderly Patients

Efficacy of CeraVe® Moisturizing Cream on Skin Pruritus in Elderly Patients

The goal of this clinical trial is to evaluate the CeraVe® moisturizing cream's efficiency on the improvement of skin barrier in patients with chronic elderly pruritus. The main questions it aims to answer are:

type of study: clinical trial participant population:in patients with chronic elderly pruritus [question 1] Evaluate the CeraVe® moisturizing cream's efficiency on the improvement of skin barrier in patients with chronic elderly pruritus, including improvements of redness, dryness/squamation, itching, burning, tingling, tightness and other factors.

[question 2] Evaluate the tolerance of CeraVe® Moisturising Cream. [question 3] Evaluate the product experience of patients who were utilizing CeraVe® Moisturising Cream.

This trial utilizing simple randomization, the left and right calves of paticipants were randomly divided into test side(applicating CeraVe® Moisturising Cream ) and control side (applicating Standard Cream)according to random number representation. Grouping results were double-blinded.

Inclusion Criteria:

• patients age≥60 years old(male or female).
• Clinician evaluates dry pruritus or patient complains of pruritus, which lasts for more than 1 month.
• Patients informed consent to the purpose and content of the research, willing to cooperate with follow-up observation. Have good communication and understanding skills.
• Patients are willing to share photos for medical research purpose.

Exclusion Criteria:

• Patients with bacterial and/or viral infections in the acute phase of skin inflammation
• The affected area is complicated by other skin diseases that may affect the efficacy evaluation
• Those who are allergic to the ingredients of this product or with allergic constitution
• Patients who have severe heart, brain, lung, or liver damage.
• Those who have received systemic or local antiallergic drug treatment within 2 weeks before enrollment of this study.
• Those who attending other clinical drug trials within 4 weeks before enrollment of this study.
• Patients with a history of alcohol or drug abuse.
• Patients who are unwilling to sign the informed consent form, and those who are unwilling to cooperate.